新发炎症性肠病中放射性原发性硬化性胆管炎的前瞻性队列研究
该前瞻性人群队列研究纳入丹麦某地区2021-2023年新诊断的成人溃疡性结肠炎或克罗恩病患者,提供磁共振胰胆管成像检查。389例接受MRCP的患者中31例(8.0%)诊断为放射性PSC,合并PSC样病变后总患病率为9.8%,仅51.6%患者有肝功能异常。放射性PSC在广泛结肠炎患者中更常见,并与随访期间更高的IBD相关住院率和生物制剂使用率相关。
要点
- 新发IBD患者中放射性PSC或PSC样病变的总患病率为9.8%。
- 仅51.6%的放射性PSC患者表现为肝功能生化异常。
- 广泛结肠炎患者放射性PSC患病率高于非广泛结肠炎患者(12.3% vs 4.3%)。
核心结论
- 新发IBD患者中约1/10存在放射性PSC或PSC样病变,且常无生化异常。
- IBD起病时放射性PSC负担可能高于既往预期,但长期临床意义尚不确定。
- 在推荐MRCP作为IBD诊断时筛查手段前,需长期随访和成本效益分析确认。
研究设计与样本
- 前瞻性人群为基础的新发队列研究,纳入丹麦某定义地区2021-2023年新诊断的成人UC或CD患者。
- 所有患者均接受磁共振胰胆管成像(MRCP)检查,主要结局为放射性PSC患病率。
- 527例患者中389例(73.8%)接受MRCP,其中UC 242例、CD 147例。
- 中位随访2.0年(四分位距1.6-2.0年;范围1.0-2.0年)。
主要发现
- 31例(8.0%)诊断为放射性PSC,其中UC 16例(6.6%)、CD 15例(10.2%)。
- 7例(1.8%;UC 5例[2.1%]、CD 2例[1.4%])有非诊断性PSC样病变,合并患病率为9.8%。
- 仅51.6%(16/31)的放射性PSC患者表现为肝功能生化异常。
关键数值与推荐
- 放射性PSC患病率:31/389(8.0%);UC 16/242(6.6%),CD 15/147(10.2%)。
- 合并非诊断性PSC样病变后总患病率:38/389(9.8%)。
- 肝功能生化异常比例:16/31(51.6%)。
临床怎么用
- 对新发IBD患者应考虑PSC可能,即使肝功能生化正常。
- 广泛结肠炎患者可能为放射性PSC的高危人群,需加强监测。
- MRCP在IBD诊断时的筛查价值尚待长期随访和成本效益分析确认。
局限性
- 仅73.8%的患者接受了MRCP,存在选择偏倚可能。
- 中位随访仅2.0年,长期临床意义尚不确定。
- 研究为单地区人群,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with long-term ulcerative colitis (UC) and Crohn's disease (CD). We aimed to determine its prevalence, clinical features, and impact in patients with newly diagnosed UC and CD. METHODS: In a prospective population-based inception cohort, all adult patients with newly diagnosed UC or CD in a defined region of Denmark (2021-2023) were offered magnetic resonance cholangiopancreatography (MRCP). Primary outcome was the prevalence of radiological PSC. Patients were followed-up prospectively for a median of 2.0 years (interquartile range, 1.6-2.0 years; range, 1.0-2.0 years). RESULTS: Of 527 patients, 389 patients (73.8%) (UC, 242; CD, 147) underwent MRCP, of whom 31 patients (8.0%) were diagnosed with radiological PSC (UC, 16 [6.6%]; CD, 15 [10.2%]), whereas 7 patients (1.8%; UC, 5 [2.1%]; CD, 2 [1.4%]) had nondiagnostic PSC-like lesions, yielding a combined prevalence of 9.8%. Only 51.6% (16/31) presented with abnormal liver biochemistry. PSC prevalence was higher in patients with extensive colitis (9/73 [12.3%] vs 7/164 [4.3%]; P = .02), but did not differ by age or sex, and was associated with higher rates of inflammatory bowel disease (IBD)-related hospitalization (41.9% vs 23.4%; P = .03) and biological therapies (38.7% vs 21.4%; P = .03) during follow-up. CONCLUSIONS: Radiological PSC or PSC-like lesions were present in 1 in 10 patients with incident IBD, often without biochemical abnormalities. These findings suggest a higher burden of radiological PSC at IBD onset than previously anticipated, although the long-term clinical significance remains uncertain. Although MRCP at IBD diagnosis may prove clinically beneficial, confirmation from long-term follow-up and cost-effectiveness analyses is required before it can be recommended for screening.
引用
- Attauabi M, Madsen GR, Møller J, et al. Radiological Primary Sclerosing Cholangitis in Incident Inflammatory Bowel Disease - A Prospective Copenhagen Inflammatory Bowel Disease Inception Cohort Study. Clin Gastroenterol Hepatol. 2026. PMID: 42685962. doi:10.1016/j.cgh.2026.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。